AbbVie has agreed to pay $1.4 billion to buy Aliada Therapeutics. The acquisition will give AbbVie control of an Alzheimer’s ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

The purchase is the latest in a slew of efforts to invest in its neuroscience portfolio as Humira faces generic competition.

Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the mid-stage study has been tied to one death. | Early data suggest ...

The clumping of amyloid beta in the brain to form plaques is one the hallmarks of AD, and the 'amyloid hypothesis' suggests they are a primary driver for the neurodegeneration seen in the disease.

Alzheimer's disease, the leading cause of dementia, affects over 55 million people worldwide. The disease is characterized by ...

The technology – called Antibody Transport Vehicle (ATV): Amyloid beta – can be used to help amyloid-targeting drugs cross the blood brain barrier (BBB) more effectively, say the partners.

In a small early trial using a transcranial magnetic stimulation procedure, scientists were able to target a key brain ...

is recommending the diagnosis of AD be limited to individuals with mild cognitive impairment or dementia and not be applied ...

Zizyphi spinosi semen demonstrates neuroprotective effects, improving cognitive function and reducing amyloid and tau pathology in models of aging and dementia.

Drs Pavan Brahmbhatt and Amit Agarwal discuss best practices for managing amyloid-related imaging abnormalities in patients ...

An international team led by researchers at the University of Toronto has developed an efficient and robust system, using the C. elegans nematode, to screen for compounds that can stop the growth of ...